Oxford BioTherapeutics vs Symberix
Oxford BioTherapeutics
Redefining the cancer-immune synapse for novel immune checkpoint mechanisms
66 employees · est. 2004 · Oxford, United Kingdom
Oxford BioTherapeutics is the older company (2004 vs 2013); Oxford BioTherapeutics is the larger of the two.
Side-by-Side Comparison
| Metric | Oxford BioTherapeutics | Symberix |
|---|---|---|
| Founded | ||
| Founded | 2004 older | 2013 |
| Headquarters | ||
| Headquarters | Oxford, United Kingdom | United States |
| Employees | ||
| Employees | 66 larger | 3 |
| Industry | ||
| Industry | Biotechnology, Health Care, Health and Wellness | Biotechnology, Health Care |
| Total Funding | ||
| Total Funding | $28.09M | Not tracked yet |
| Funding Rounds | ||
| Funding Rounds | 11 | Not tracked yet |
| Services | ||
| Services | Development of targeted cancer therapies, Integration of OGAP-Verify proteomic platform, Clinical-stage asset management, Therapeutic antibody generation | Not tracked yet |
| Target Customers | ||
| Target Customers | Oncology patients, Pharmaceutical partners, Biotechnology collaborators | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Clinical Stage OncologyImmuno-OncologyAntibody-Drug ConjugatesCancer TherapeuticsImmune Checkpoint MechanismsTargeted Medicines +9 | MicrobiomeDrug DiscoveryPharmaceuticalsSymbiotic DrugsGI DiseasesCancer Therapeutics +8 |
| Website | ||
| Website | oxfordbiotherapeutics.com | symberix.com |
About Oxford BioTherapeutics
Oxford BioTherapeutics (OBT), founded in 2004 and headquartered in the United Kingdom, is at the forefront of cancer therapeutics innovation. The company is uniquely positioned with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies aimed at addressing sign...
About Symberix
Symberix is an early-stage biotechnology startup with a vision to revolutionize pharmaceutical control of the microbiome. The company, founded in 2013 as a spin-out of the University of North Carolina at Chapel Hill, is focused on pioneering the development of symbiotic drugs that aim to improve hum...
Also comparing in this category
We will tell you when either one moves
BounceWatch watches Oxford BioTherapeutics and Symberix for new funding, fast hiring, new executives and a change of software vendor. When one happens, it is in your next e-mail.
Get notified when Oxford BioTherapeutics or Symberix moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Frequently Asked Questions
Compare Oxford BioTherapeutics with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Oxford BioTherapeutics on 22 Mar 2026, and Symberix on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
